Amarin Corp ADR (AMRN)
$1.26
0.02 (1.61%)
AMRN Stock Quote Delayed 30 Minutes
3 Biotech Stocks to Avoid Like the Plague
Investors are looking for bargains in the biotech sector. But these three biotech stocks should be avoided at all costs.
11 Best Stocks to Buy for 2023
INSIDE: Investing legend Louis Navellier reveals his Top 11 Stocks for 2023 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
513.16M
PE Ratio
-5.73
EPS
-0.22
Volume (Avg. Vol.)
2.35M
Day's Range
$1.22 - $1.31
52-Week Range
$1.04 - $2.23
Dividend & Yield
N/A (N/A)
AMRN Stock Predictions, Articles, and Amarin Corp ADR News
AMRN Stock News: Why Amarin Shares Are Climbing Today
AMRN stock is climbing higher Thursday thanks to good news from a clinical trial in China. Here's what you should know about Amarin now.
5 Top Stock Trades for Thursday: PTON, DOCU, MDB, SDC, AMRN
Peloton, Docusign, MongoDB, Amarin and SmileDirectClub were our top stock trades for Thursday. So, let's take a closer look at the charts.
Stock Market Today: Another $2 Trillion?; Amarin Bites the Dust
Amarin shares fell 70% on the day, while we're already talking about another $2 trillion plan. Here's the stock market today.
Amarin News: AMRN Stock Plunges 71% on Court Ruling
Amarin (AMRN) news for Tuesday concerning a generic rival lawsuit over one of its drugs has AMRN stock taking a nosedive.
Even If It Hurts Amarin Stock, Reducing the Vascepa Sales Push Is Smart
n late February, I argued that the company’s move to double its U.S. sales force to 800 to meet the demand for Vascepa, along with the future approvals of the drug in Europe, Canada and elsewhere, made Amarin stock a smart buy despite the apparent risk.
Amarin Stock Gets Cheaper, but Serious Questions Linger
Amarin was supposed to have a huge 2020 after securing a key FDA approval. Instead, the stock is going down, and the CEO is selling shares.
Why It’s the Perfect Time to Buy Amarin Stock Now
If you've been waiting for a chance to buy a dip in Amarin stock, the wait is over. Here's what you need to know about the company.
Amarin Stock Looks Like a Heart-Healthy Buy on the Dip
Amarin stock has hit a wall, potentially because of generics litigation. But I think this has been an overreaction. Here’s a look at why.
Amarin Stock: When Good Results Aren’t Enough
Amarin stock is a risk/reward story and it offers plenty of both. It's probably best suited for investors who can deal with volatility.
3 Big Stock Charts for Tuesday: Amarin, Campbell Soup, and Church & Dwight
Tuesday's big stock charts feature three big winners in Monday's big rally — all of which have hopes for further upside ahead.
Confounding Decline Creates an Opportunity in Amarin Stock
Amarin stock has declined by nearly a quarter so far in 2020 — on little news. That lower valuation makes AMRN an intriguing candidate on the dip.
4 Top Stock Trades for Thursday: AMRN, LOW, BAC, CCL
Amarin, Bank of America, Carnival Cruise and Lowe's were our top stock trades from Wednesday. That said, here's a look at the charts.
